To dry or not too dry: should we be more tolerant of stable subretinal fluid in patients receiving anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration?
Centre for Eye Research Australia (CERA), Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Hessom
H
Razavi
Marsden Eye Specialists, Parramatta, New South Wales, Australia.
Jennifer
J
Arnold
Centre for Eye Research Australia (CERA), Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Robyn
R
Guymer
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D058471:Subretinal Fluid; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A